Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 1Breast Neoplasms 1

Interventions

Specimen Handling 302Magnetic Resonance Spectroscopy 261pembrolizumab 249Carboplatin 184Cyclophosphamide 175Biopsy 167Cisplatin 157Gemcitabine 134Paclitaxel 130Bevacizumab 123fludarabine 115Nivolumab 108Radiotherapy 107Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 78Dexamethasone 76Pemetrexed 72Rituximab 69Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 64Doxorubicin 63Standard of Care 62Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × serabelisib × 90 days × Clear all
NCT07558733 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Faeth Therapeutics

Phase 1/2 Recruiting
32 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡